The company also said that a previously granted EUA for its Alinity m SARS-CoV-2 assay has been expanded to include asymptomatic individuals and pooled testing.
R-Pharm, Illumina's strategic partner in Russia and the Commonwealth of Independent States (CIS), led the registration process with the Russian regulatory agency.
The test is designed to assess the risk of a person developing severe disease if they contract COVID-19 based on a combination of genetic and clinical factors.
The company sold two series of senior notes totaling $500 million that it said it plans to use to repay outstanding debt and for general corporate purposes.
The firm said that with the addition of a target for SARS-CoV-2, its high-throughput NxTag syndromic respiratory panel includes 19 viral and two bacterial targets.
QiaCube Connect MDx is designed specifically for IVD applications, and automates DNA, RNA, and protein sample processing using Qiagen spin column technology.
Billable test volume for the company's ConfirmMDx and SelectMDx prostate cancer test fell year over year, but rose sequentially from the third quarter.
